J&J Medical Connect
TECVAYLI®

(teclistamab-cqyv)

J&J Medical Connect

Connect with us

Connect with us

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

TECVAYLI® (teclistamab-cqyv)

Medical Information

TECVAYLI - Interference with Immunofixation Assays

Last Updated: 02/03/2026

SUMMARY  

  • The interference of TECVAYLI with immunofixation methods required to confirm complete response (CR) per International Myeloma Group (IMWG) criteria have not been currently assessed.1
  • Since teclistamab is a modified immunoglobulin G (IgG) lambda antibody, interference with immunofixation assays could not be excluded.2
  • Based on interim results (data cutoff: 16 March 2022) from patients who received teclistamab at the recommended phase 2 dose in the pivotal trial, CR was adjudicated in a similar fraction of subjects with IgG kappa and IgG lambda M protein, although time to CR was slightly longer for subjects with IgG lambda MM.2
  • Although the small sample size does not allow for definitive conclusions, these current data would suggest that the interference of teclistamab in the assessment of CR by immunofixation might be limited.2
  • Other relevant literature was identified in addition to the data summarized above.3-6 

Literature Search

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File databases (and/or other resources, including internal/external databases) was conducted on 02 February 2026.

 

References

Show
1 Data on File. TECVAYLI Interference with Immunofixation Assays written communication.; 2023.  
2 Teclistamab EPAR Assessment Report 21 July 2022. [cited 2026 February 02]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/tecvayli-epar-public-assessment-report_en.pdf
3 Larkin J, Swartchick C, Kohlhagen M, et al. Teclistamab: a bispecific monoclonal IgG lambda therapeutic is observable on serum immunofixation and mass-fix. Clinical Chemistry. 2025;71 (Suppl. 1):hvaf086.576.  
4 Pello R, Iglesias MÁ, Vidal R, et al. Mass spectrometry profiling of therapeutic antibodies in multiple myeloma: m/z features and concordance with immunofixation electrophoresis. Biomedicines. 2025;13(12):2933.  
5 Kadkhoda K, Faiman B, Valent J, et al. The first case of teclistamab interference with serum electrophoresis and immunofixation. Clin Chem Lab Med (CCLM). 2025;63(7):e172-e174.  
6 Whitt A, McCoy MH, Jortani SA. B-342 Teclistamab interference in serum protein electrophoresis and serum immunofixation electrophoresis in patients with recurrent or relapsed multiple myeloma. Clin Chem. 2024;70(Supplement_1):i264-265.